- Home
- GNS vs CGTX Comparison
GNS vs CGTX Comparison
Compare GNS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNS
- CGTX
- Stock Information
- Founded
- GNS 2002
- CGTX 2007
- Country
- GNS Singapore
- CGTX United States
- Employees
- GNS N/A
- CGTX N/A
- Industry
- GNS Other Consumer Services
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNS Real Estate
- CGTX Health Care
- Exchange
- GNS Nasdaq
- CGTX Nasdaq
- Market Cap
- GNS 17.8M
- CGTX 20.5M
- IPO Year
- GNS 2022
- CGTX 2021
- Fundamental
- Price
- GNS $0.97
- CGTX $0.30
- Analyst Decision
- GNS
- CGTX Strong Buy
- Analyst Count
- GNS 0
- CGTX 5
- Target Price
- GNS N/A
- CGTX $5.63
- AVG Volume (30 Days)
- GNS 11.5M
- CGTX 1.9M
- Earning Date
- GNS 04-30-2025
- CGTX 08-07-2025
- Dividend Yield
- GNS N/A
- CGTX N/A
- EPS Growth
- GNS N/A
- CGTX N/A
- EPS
- GNS N/A
- CGTX N/A
- Revenue
- GNS $7,912,718.00
- CGTX N/A
- Revenue This Year
- GNS $233.65
- CGTX N/A
- Revenue Next Year
- GNS $570.20
- CGTX N/A
- P/E Ratio
- GNS N/A
- CGTX N/A
- Revenue Growth
- GNS N/A
- CGTX N/A
- 52 Week Low
- GNS $0.21
- CGTX $0.22
- 52 Week High
- GNS $3.20
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- GNS 89.26
- CGTX 48.87
- Support Level
- GNS $0.34
- CGTX $0.25
- Resistance Level
- GNS $0.71
- CGTX $0.33
- Average True Range (ATR)
- GNS 0.14
- CGTX 0.03
- MACD
- GNS 0.07
- CGTX 0.00
- Stochastic Oscillator
- GNS 83.51
- CGTX 58.69
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.